Characteristics of patients treated according to HOVON 44 protocol
| . | DHAP-arm . | R-DHAP-arm . |
|---|---|---|
| Patients, no. | 112 | 113 |
| Histology, %* | ||
| DLBCL | 88 | 91 |
| FL grade III | 10 | 6 |
| Other | 2 | 3 |
| Prior treatment, % | ||
| CHOP-21 | 63 | 64 |
| CHOP-14 | 5 | 6 |
| CHOP-intensified | 15 | 11 |
| Other | 17 | 19 |
| Rituximab | 4 | 4 |
| Time since upfront treatment, % | ||
| 6 mo or less | 13 | 18 |
| 6 to 12 mo | 33 | 39 |
| More than 12 mo | 54 | 43 |
| . | DHAP-arm . | R-DHAP-arm . |
|---|---|---|
| Patients, no. | 112 | 113 |
| Histology, %* | ||
| DLBCL | 88 | 91 |
| FL grade III | 10 | 6 |
| Other | 2 | 3 |
| Prior treatment, % | ||
| CHOP-21 | 63 | 64 |
| CHOP-14 | 5 | 6 |
| CHOP-intensified | 15 | 11 |
| Other | 17 | 19 |
| Rituximab | 4 | 4 |
| Time since upfront treatment, % | ||
| 6 mo or less | 13 | 18 |
| 6 to 12 mo | 33 | 39 |
| More than 12 mo | 54 | 43 |
Time course of a cycle of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) could be 14 days (CHOP-14) or 21 days (CHOP-21). Intensified CHOP consisted of a higher dose of cyclophosphamide (1000 mg/m2) and doxorubicin (70 mg/m2) every 2 weeks.
DLBCL indicates diffuse large B-cell lymphoma; and FL grade III, follicular grade III NHL.
Histology according to WHO classification.